9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA
As autumn season approaches the EMA and ECDC held a press briefing to provide latest information on respiratory diseases as well as vaccines and treatments available
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Nirsevimab is a monoclonal antibody that binds to the RSV fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season.
The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
RSV causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon.
ESWI Airborne: Burden of Disease
Burden of disease - A focus on acute respiratory viruses in older adults
Why should older adults be particularly careful of acute respiratory viruses? What are risk factors for adverse outcomes? Why is RSV typically under-diagnosed in adults compared with flu and what are some of the long-term impacts?
ESWI Airborne: Burden of Disease
Burden of disease - The economic and societal impact of acute respiratory viruses
The shocking numbers of babies and children who die, or who are in need of care, coupled with the rising number of undiagnosed older adults puts a significant burden from RSV on health systems.
Policy & Recommendations
European Commission authorises first vaccine to protect older adults from RSV infection
The EC has authorised Arexvy, the first vaccine to protect adults aged 60 years and older, against RSV. This decision marks an important step and has been particularly awaited in light of the increased RSV infections in the EU last winter.
Progress Report: Reducing the Burden of RSV across the Lifespan
The National Foundation for Infectious Diseases (NFID) supports RSV education by engaging key audiences, sharing firsthand experiences of RSV among all age groups, and providing resources to help raise awareness of the burden of disease.
ReSViNET's RSV Dashboard is 𝐋𝐈𝐕𝐄!
ReSViNET Foundation is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. The dashboard will help simplify tracking changes in RSV seasonality globally.
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
RSV infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
Whether vaccination during pregnancy could reduce the burden of RSV associated lower respiratory tract illness in newborns and infants is uncertain.
Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study
Early-life severe RSV infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear.